The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya

Lynette Isabella Ochola-Oyier; John Okombo; Leah Mwai; Steven M. Kiara; Lewa Pole; Kevin K.A. Tetteh; Alexis Nzila; Kevin Marsh

doi:10.1128/AAC.03522-14

The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya

Lynette Isabella Ochola-Oyier^*
, John Okombo
, Leah Mwai
, Steven M. Kiara
, Lewa Pole
, Kevin K.A. Tetteh
, Alexis Nzila
, Kevin Marsh

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P=0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).

Original language	English
Pages (from-to)	1770-1775
Number of pages	6
Journal	Antimicrobial Agents and Chemotherapy
Volume	59
Issue number	3
DOIs	https://doi.org/10.1128/AAC.03522-14
State	Published - 1 Mar 2015

Bibliographical note

Publisher Copyright:
Copyright © 2015, Ochola-Oyier et al. Copyright © 2015, American Society for Microbiology. All Rights Reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.03522-14

Cite this

@article{c04c4e7b5a7c464192d549e24b59ca5a,

title = "The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya",

abstract = "The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P=0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).",

author = "Ochola-Oyier, \{Lynette Isabella\} and John Okombo and Leah Mwai and Kiara, \{Steven M.\} and Lewa Pole and Tetteh, \{Kevin K.A.\} and Alexis Nzila and Kevin Marsh",

year = "2015",

month = mar,

day = "1",

doi = "10.1128/AAC.03522-14",

language = "English",

volume = "59",

pages = "1770--1775",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya

AU - Ochola-Oyier, Lynette Isabella

AU - Okombo, John

AU - Mwai, Leah

AU - Kiara, Steven M.

AU - Pole, Lewa

AU - Tetteh, Kevin K.A.

AU - Nzila, Alexis

AU - Marsh, Kevin

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P=0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).

AB - The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P=0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).

UR - https://www.scopus.com/pages/publications/84923253946

U2 - 10.1128/AAC.03522-14

DO - 10.1128/AAC.03522-14

M3 - Article

C2 - 25534732

AN - SCOPUS:84923253946

SN - 0066-4804

VL - 59

SP - 1770

EP - 1775

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 3

ER -

The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya

Abstract

Bibliographical note

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this